- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02457091
Project Get Fit With MS: Guidelines for Exercise Training and Fitness Outcomes in MS (GetFit)
December 1, 2015 updated by: University of Illinois at Urbana-Champaign
Project GET FIT With MS: Guidelines for Exercise Training and Fitness Outcomes in MS
The purpose of this study is to test different types of exercise training for people with multiple sclerosis (MS).
The exercise program is based on physical activity guidelines that have been developed specifically for people with MS.
The investigators believe these guidelines will be effective for improving physical fitness and function in persons with mild-to-moderate MS.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Most adults with multiple sclerosis (MS) are physically inactive.
One approach to address physical inactivity in this population has involved the provision of physical activity guidelines.
Such physical activity guidelines are an important tool for exercise prescription, promotion, and monitoring, and recommend that people with MS "participate in at least 30 minutes of moderate intensity aerobic activity 2 times per week and strength training exercises for major muscle groups 2 times per week."
The guidelines were developed from a systematic literature review and have yet to be tested for efficacy in improving fitness or other outcomes.
This study will test that efficacy of aerobic and resistance training alone and in combination (based on the MS physical activity guidelines) for improving physical fitness and other outcomes (e.g., walking, thinking, MS symptoms) in persons with MS who have mild-to-moderate disability.
Such an examination will be important to confirm the efficacy of the exercise prescription for people with MS and health-care providers.
The investigators will further perform an exploratory analysis of blood biomarkers and eye imaging parameters to examine some of the mechanisms of exercise training effects in persons with MS.
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Urbana-Champaign, Illinois, United States, 61801
- University of Illinois at Urbana-Champaign
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 54 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- a definite diagnosis of MS
- self-reported Expanded Disability Status Scale (EDSS) score < 6.0 or Patient Determined Disability Steps (PDDS) scale score ≤ 3.0
- relapse free in past 30 days
- willing and able to visit the University of Illinois at Urbana-Champaign for on seven occasions (two testing visits; five training visits) and participate in a 6-month home-based exercise program
- non-exerciser
- asymptomatic and physician approval for undertaking exercise testing and training
Exclusion Criteria:
- currently pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Stretching exercise
The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
|
The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
|
|
Experimental: Resistance exercise
The resistance condition will consist of 1-3 sets, 10-15 repetitions of 12 exercises targeting lower body, upper body, and core muscle groups performed 2 days per week.
|
strength training consists of 1-3 sets , 10-15 repetitions of 10 exercises targeting lower body, upper body and core muscle groups
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physical fitness (aerobic and muscular)
Time Frame: 0 and 6 months
|
Physical fitness determined by VO2 peak using a computer-driven cycle ergometer Muscular fitness determined by a seated dynamometer machine for leg strength and a hand dynamometer for upper body strength
|
0 and 6 months
|
|
Walking and physical function
Time Frame: 0 and 6 months
|
A timed 25-Foot walk, a 6 -minute walk, walking on a GaitRite electronic walkway, 9-hole peg test and the use of a force platform will measure walking and physical function.
|
0 and 6 months
|
|
Cognition
Time Frame: 0 and 6 months
|
The Brief International Cognitive Assessment for MS battery will be used.
|
0 and 6 months
|
|
Physical activity
Time Frame: 0 and 6 months
|
an accelerometer along with the Godin Leisure Time Physical Activity Questionnaire and 7-day Physical Activity Recall Questionnaire will be used to measure physical activity.
|
0 and 6 months
|
|
Patient-rated outcomes
Time Frame: 0 and 6 months
|
Self reporting questionnaires on fatigue, mobility, anxiety, depression, QoL, and social cognitive theory variable (e.g.
Exercise Self-Efficacy Scale, Late-life function and disability scale)
|
0 and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body composition
Time Frame: 0 and 6 months
|
DXA scan
|
0 and 6 months
|
|
OCT Eye imaging
Time Frame: 0 and 6 months
|
0 and 6 months
|
|
|
Cardiovascular function
Time Frame: 0 and 6 months
|
ultrasonography techniques for arterial size, stiffness and blood pressure along with an ECG
|
0 and 6 months
|
|
Blood biomarkers
Time Frame: 0 and 6 months
|
Circulating inflammatory markers, cytokines and growth factors
|
0 and 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neurological examination
Time Frame: 0 and 6 months
|
0 and 6 months
|
|
|
Exercise training parameters
Time Frame: 24 weeks
|
strength-training program or a stretching and limbering program
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Lara Pilutti, PhD, University of Illinois at Urbana-Champaign
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2013
Primary Completion (Actual)
September 1, 2014
Study Completion (Actual)
December 1, 2014
Study Registration Dates
First Submitted
March 17, 2014
First Submitted That Met QC Criteria
May 26, 2015
First Posted (Estimate)
May 29, 2015
Study Record Updates
Last Update Posted (Estimate)
December 3, 2015
Last Update Submitted That Met QC Criteria
December 1, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NMSS IL-0010
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Stretching exercise
-
Tokat Gaziosmanpasa UniversityCompleted
-
Dragan MijatovićCompletedStretchBosnia and Herzegovina
-
Eastern Mediterranean UniversityRecruiting
-
Istanbul University - Cerrahpasa (IUC)CompletedEffects of PNF and Static Stretching on Architecture and Viscoelastic Properties of Hemiplegic ElbowStroke | Spasticity, MuscleTurkey
-
European Institute of OncologyFondazione Umberto VeronesiCompleted
-
Riphah International UniversityCompletedMusculoskeletal PainPakistan
-
University of SaskatchewanCanadian Institutes of Health Research (CIHR)Recruiting
-
University of SaskatchewanCanadian Institutes of Health Research (CIHR)Completed
-
Children's Hospital of PhiladelphiaBoston Children's Hospital; University at BuffaloCompletedBrain Concussion | Mild Traumatic Brain Injury | Acute Brain InjuryUnited States
-
Spanish Breast Cancer Research GroupInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz; Faculty...CompletedBreast Cancer | Luminal BSpain